TORONTO, Oct. 31, 2023 /CNW/ – NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a leader in predictive clinical trial analytics, is thrilled to announce that it has entered into a Master Service Agreement with a large public listed biopharmaceutical company.
The agreement paves the way for collaboration, whereby NetraMark will employ its unique Generative AI technology platform to analyze clinical trial data from select candidate medicines of the biopharmaceutical company. The primary objective being to discover specific subpopulations and shed light on unique patient enrichment paradigms related to drug and placebo responses.
Josh Spiegel, President of NetraMark, expressed his enthusiasm: “We are elated to forge this relationship. Our advanced Generative AI solutions are poised to offer profound insights into patient populations involved in clinical trials. This collaboration aims to enhance the success rates of late-stage clinical trials, aligning seamlessly with the biopharmaceutical company’s dedication to expediting the development of innovative treatments for conditions with significant unmet medical needs.
The agreement follows an extensive and rigorous evaluation of NetraMark by the biopharmaceutical company, including a comprehensive vendor qualification audit, ensuring adherence to the highest standards of Good Clinical Practice (GCP).
NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI) / Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI / ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and / or efficacy of treatment.
For further details on the Company please see the Company’s publicly available documents filed on the System for Electronic Document Analysis and Retrieval (SEDAR).
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation including statements regarding the Company entering into master service agreements and additional contractual engagements and the maintenance of NetraAI which are based upon NetraMark’s current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown, risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors.
When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com including our Management’s Discussion and Analysis for the year ended September 30, 2022. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
SOURCE NetraMark Holdings Inc.
For further information: Swapan Kakumanu – CFO, firstname.lastname@example.org, 403-681-2549